<DOC>
	<DOC>NCT01644253</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of TRU-016 when when administered in combination with rituximab or obinutuzumab, in combination with idelalisib and rituximab, or in combination with ibrutinib in patients with chronic lymphocytic leukemia (CLL).</brief_summary>
	<brief_title>Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Diagnosis of CLL by 2008 IWCLL criteria and with Rai stage intermediate or high risk CLL No prior therapy for CLL for Cohorts 1, 3 and 4. For Cohort 2, 13 prior treatments. For Cohort 5, patients must have failed to respond or relapsed after 1 or more treatment regimens. For Cohort 6, patients who have been receiving ibrutinib for at least 12 months, have not had a CR, and in whom no cysteine 481 mutation is detected. For Cohort 7, patients who are receiving ibrutinib with stable disease and now have the cysteine 481 mutant clone present at levels of &gt;1%. At least one of the following criteria for active disease requiring treatment: progressive splenomegaly and/or lymphadenopathy; anemia or thrombocytopenia due to bone marrow involvement; or progressive lymphocytosis with an increase of &gt;50% over a 2month period or an unanticipated doubling time of less than 6 months For Cohorts 1, 3 and 4, contraindication to chemotherapy as firstline therapy due to patient age, comorbidity or patient preference Age &gt;/= to 18 years ECOG performance status of &lt;/= 2 Life expectancy &gt; 6 months in opinion of Investigator Serum creatinine, total bilirubin, ALT/SGPT &lt;/= 2.0 x upper limit of normal ANC &gt;/= 800/mm3 Platelets &gt;/= 30,000/mm3 For Cohorts 1, 3 and 4 only: Has received treatment with rituximab, alemtuzumab, ofatumumab or any other chemotherapeutic agent for CLL Has received an investigational therapy within 30 days of first dose of study drug Previous or concurrent additional malignancy Clinically significant pulmonary dysfunction, active infection, prior allogeneic bone marrow transplant, active autoimmune disease Positive serology for HIV or hepatitis C Hepatitis B surface antigen or hepatitis B core antibody positive Pregnant or breastfeeding Known current drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>previously untreated chronic lymphocytic leukemia</keyword>
</DOC>